ReviewElectrolyte & blood pressure : E & BP2008
Renin-Angiotensin system - considerations for hypertension and kidney.
Review in Electrolyte & blood pressure : E & BP, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 91 citations in OpenAlex.
- Loss of the liver circadian clock affects the expression of intrarenal renin-angiotensin system components.Scientific reports · 2025Article
- RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.Journal of cardiovascular translational research · 2025Review
- Sex-Specific Differences in the Pathophysiology of Hypertension.Biomolecules · 2025Review
- Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Potential Modulator of the Renin-Angiotensin System (RAS) Pathway in Hypertension Development.Life (Basel, Switzerland) · 2024Article
- Non-dialyzable uremic toxins and renal tubular cell damage in CKD patients: a systems biology approach.European journal of medical research · 2024Article
- Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury.Pharmacological research · 2024Article
- A systems biology-based mathematical model demonstrates the potential anti-stress effectiveness of a multi-nutrient botanical formulation.Scientific reports · 2024Article
- Vasorelaxant and Blood Pressure-Lowering Effects ofInternational journal of molecular sciences · 2024Article
- Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview.The journal of headache and pain · 2024Review
- Antihypertensive Effect of Milk Fermented byFood science of animal resources · 2024Article
- Effects of intrarenal angiotensin 1-7 infusion on renal haemodynamic and excretory function in anaesthetised two-kidney one-clip and deoxycorticosterone acetate-salt hypertensive rats.Experimental physiology · 2023Article
- Article
- Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Review
- Deciphering mechanisms of action of ACE inhibitors in neurodegeneration usingFrontiers in neuroscience · 2023Review
- Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome.Advances in nutrition (Bethesda, Md.) · 2022Review
- Article
- Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions.Circulation research · 2022Review
- Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review.Journal of pharmaceutical analysis · 2022Review
- Unraveling the Differentially Articulated Axes of the Century-Old Renin-Angiotensin-Aldosterone System: Potential Therapeutic Implications.Cardiovascular toxicology · 2022Review
- Vitamin C Lowers Blood Pressure in Spontaneously Hypertensive Rats by Targeting Angiotensin-Converting Enzyme I Production in a Frequency-Dependent Manner.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidneys play a fundamental role in the long-term control of arterial pressure by regulating sodium balance and extracellular fluid volume. The renin-angiotensin system (RAS) is at the center of the regulation of hypertension and progressive renal injury. It has gradually become clear that not only systemic RAS, but also intrarenal RAS has specific effects in the pathogenesis and progression of hypertension and renal damage. All of the RAS components are exhibited in the kidney and intrarenal angiotensin II (Ang II) is formed by multiple mechanisms. The demonstration of much enhanced levels of Ang II within specific renal compartments points out selective local regulation of Ang II in the kidney, showing that intrarenal Ang II levels are regulated in a way different from circulating Ang II. The importance of the RAS in involving proper nephrogenesis is also well known, and suppression of the RAS during fetal development may play a key role in mediating the structural and physiological changes observed in models of fetal programming of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.